FDA’s initial vision for a compendium of clinical outcomes assessment tools includes instruments that have completed or are undergoing the agency’s formal qualification process as well as measures reflected in labeling for novel products.
However, the agency hopes to eventually broaden the scope of the compendium to include instruments that were submitted as part of efficacy supplements and to identify areas of unmet measurement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?